TBPH logo

TBPH
Theravance Biopharma Inc

1,027
Mkt Cap
$853.2M
Volume
150,354.00
52W High
$21.03
52W Low
$9.10
PE Ratio
7.51
TBPH Fundamentals
Price
$16.42
Prev Close
$16.55
Open
$16.40
50D MA
$15.97
Beta
0.58
Avg. Volume
393,786.54
EPS (Annual)
$2.06
P/B
2.93
Rev/Employee
$1.19M
$723.84
Loading...
Loading...
News
all
press releases
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?
Investors need to pay close attention to TBPH stock based on the movements in the options market lately.
Zacks·8d ago
News Placeholder
More News
News Placeholder
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Zacks·13d ago
News Placeholder
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·14d ago
News Placeholder
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate...
PR Newswire·14d ago
News Placeholder
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen cut shares of Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday...
MarketBeat·20d ago
News Placeholder
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Zacks·20d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·21d ago
News Placeholder
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings...
MarketBeat·26d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What Happened
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell...
MarketBeat·29d ago
<
1
2
...
>

Latest TBPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.